GSK chief predicts slower M&A pace

GlaxoSmithKline's M&A pace is likely to slow down, CEO Andrew Witty tells Reuters. The supply of transactions that will deliver GSK's required ROI is drying up, Witty says, after a year of brisk-paced bolt-on acquisitions. Says Witty: "I think we are in a period where they are more difficult to get at the levels we would be prepared to pay." Report

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.